North Star Asset Management Inc. Acquires Shares of 187,903 Illumina, Inc. $ILMN

North Star Asset Management Inc. bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, HoldingsChannel reports. The firm bought 187,903 shares of the life sciences company’s stock, valued at approximately $33,039,000. Illumina accounts for 1.3% of North Star Asset Management Inc.’s investment portfolio, making the stock its 21st biggest holding.

A number of other institutional investors and hedge funds have also modified their holdings of ILMN. Elyxium Wealth LLC purchased a new position in Illumina in the 4th quarter valued at about $25,000. Laurel Wealth Advisors LLC purchased a new stake in Illumina during the 4th quarter worth approximately $26,000. Fiduciary Financial Advisors purchased a new stake in Illumina during the 2nd quarter worth approximately $26,000. Activest Wealth Management increased its stake in Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after buying an additional 215 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina during the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 1.3%

ILMN opened at $227.69 on Friday. The firm has a market capitalization of $34.38 billion, a price-to-earnings ratio of 42.48, a price-to-earnings-growth ratio of 3.16 and a beta of 1.45. The company’s 50 day simple moving average is $192.98 and its two-hundred day simple moving average is $155.18. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $231.81. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the business earned $1.19 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ILMN. Leerink Partners raised their target price on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research note on Wednesday, August 5th. Citigroup lifted their target price on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Finally, Guggenheim upped their target price on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $188.40.

Insider Buying and Selling at Illumina

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,034,688 shares of company stock worth $417,970,281 in the last three months. 2.90% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.